

Patient Group Directions for the treatment of acute uncomplicated urinary tract infection (UTI) in non-pregnant female patients over 16 years of age

Patient assessment form

Patient Name & address:	Click or tap here to enter text.	Date of Birth /CHI:	Click or tap here to enter text.
Date of assessment:	Click or tap to enter a date.	Patient is aware that GP will informed:	Yes <input type="checkbox"/> No <input type="checkbox"/>

Patient clinical picture and related appropriate actions

Symptom assessment	Yes	No	Actions
Symptom of dysuria (pain or burning when passing urine)	<input type="checkbox"/>	<input type="checkbox"/>	Consider treatment if BOTH dysuria and frequency OR three or more of the following symptoms are present: <ul style="list-style-type: none"> • Dysuria • Frequency • Urgency • Suprapubic tenderness Support the diagnostic process with dipstick testing if available
Symptom of frequency (needing to pass urine more often than usual)	<input type="checkbox"/>	<input type="checkbox"/>	
Symptom of urgency (little warning of the need to pass urine)	<input type="checkbox"/>	<input type="checkbox"/>	
Symptom of suprapubic tenderness (pain/tenderness in lower abdomen)	<input type="checkbox"/>	<input type="checkbox"/>	
Frank haematuria (blood in urine)	<input type="checkbox"/>	<input type="checkbox"/>	If unexplained or specific exclusion criteria apply – do not treat and REFER to GP/OOH If likely to be related to UTI – treatment may be provided
Vaginal discharge or irritation	<input type="checkbox"/>	<input type="checkbox"/>	If new/unexplained – do not treat and REFER for STI assessment
Clinical features	Yes	No	Actions
Do symptoms suggest upper UTI (these may include loin pain, fever $\geq 38^{\circ}\text{C}$, rigors or systemically very unwell)?	<input type="checkbox"/>	<input type="checkbox"/>	If YES, do not treat and REFER urgently (same day) due to risk of upper UTI or sepsis
Duration of symptoms > 7 days?	<input type="checkbox"/>	<input type="checkbox"/>	If YES, treatment may be provided Ensure GP is notified that follow up may be required
Has the patient had a UTI requiring an antibiotic within the last month?	<input type="checkbox"/>	<input type="checkbox"/>	If YES, do not treat and REFER due to risk of resistant organisms

Does the patient have recurrent UTI? (≥2 episodes in last 6 months or ≥ 3 episodes in last 12 months?)	<input type="checkbox"/>	<input type="checkbox"/>	If YES, do not treat and REFER due to need for urine culture
Does patient take prophylactic antibiotics for treatment of UTI?	<input type="checkbox"/>	<input type="checkbox"/>	If YES, do not treat and REFER
Urinary catheter in situ or use of intermittent self-catheterisation?	<input type="checkbox"/>	<input type="checkbox"/>	If YES, do not treat and REFER
Is the patient currently immunosuppressed? E.g. auto-immune disease, chemotherapy, long term corticosteroids or other immunosuppressant medication?	<input type="checkbox"/>	<input type="checkbox"/>	If YES, do not treat and REFER
Pregnant – known or suspected? Planning to become pregnant in next 3 months if treating with trimethoprim?	<input type="checkbox"/>	<input type="checkbox"/>	If YES, do not treat and REFER
Breastfeeding?	<input type="checkbox"/>	<input type="checkbox"/>	If YES, treatment may be provided
Diabetes?	<input type="checkbox"/>	<input type="checkbox"/>	If YES, treatment may be provided. Refer to GP if concern over recurrent UTI or if UTI is potentially caused by side effect of medication
Confused or dehydrated?	<input type="checkbox"/>	<input type="checkbox"/>	If YES, do not treat and REFER
Known moderate to severe renal impairment or abnormality of the urinary tract or ureteric stent?	<input type="checkbox"/>	<input type="checkbox"/>	If YES, do not treat and REFER
Is the patient on any interacting medications (e.g. warfarin/trimethoprim). See current BNF/SPC for details	<input type="checkbox"/>	<input type="checkbox"/>	If YES, do not treat and REFER
Known haematological abnormalities, porphyria, folate deficiency which is uncorrected, glucose-6-phosphate deficiency?	<input type="checkbox"/>	<input type="checkbox"/>	If YES, do not treat and REFER
Known electrolyte imbalance?	<input type="checkbox"/>	<input type="checkbox"/>	If YES, do not treat and REFER
Known severe liver fibrosis / encephalopathy?	<input type="checkbox"/>	<input type="checkbox"/>	If YES, do not treat and REFER
Patient has known blood disorders such as leucopenia, megaloblastic anaemia, thrombocytopenia, agranulocytosis, or methaemoglobinaemia?	<input type="checkbox"/>	<input type="checkbox"/>	If YES, do not treat and REFER

Treatment options

Follow NHS board's first line formulary choice – this is trimethoprim in most boards.

Ideally nitrofurantoin should only be used if you have access to information about current renal function. However, if no recent eGFR is available but the patient has no history of renal problems, nitrofurantoin may be used (See Appendix 1).

Clinical features affecting therapeutic choice	Trimethoprim	Nitrofurantoin
Clinically significant drug interactions with existing medication	AVOID if significant interaction exists with current medication	
Known interstitial lung disease or poorly controlled respiratory disease	SUITABLE	AVOID due to difficulty in recognising pulmonary fibrosis secondary to nitrofurantoin
Current use of alkalinising agents	SUITABLE	AVOID or advise to stop alkalinising agent
Allergy or adverse effect to trimethoprim	AVOID	SUITABLE
Allergy or adverse effect to nitrofurantoin	SUITABLE	AVOID

Preparation options and supply method

Medicine and strength	Regimen - Health Board specific	Supply method
Nitrofurantoin 50 mg capsules	ONE capsule FOUR times daily x 12	PGD via UCF
Nitrofurantoin 50 mg tablets	ONE tablet FOUR times daily x 12	
Nitrofurantoin MR 100 mg capsules	ONE capsule TWICE daily x 6	
Trimethoprim 100 mg tablets	TWO tablets TWICE daily x 12	
Trimethoprim 200 mg tablets	ONE tablet TWICE daily x 6	
Symptomatic management only	Appropriate analgesia	UCF or OTC or existing supply

Advice	Provided (tick as appropriate)
How to take medication, possible side effects and their management.	<input type="checkbox"/>
Expected duration of symptoms - to seek medical assistance if symptoms worsen or are not resolving within 3 days	<input type="checkbox"/>
Nitrofurantoin only <ul style="list-style-type: none"> Stop taking immediately and seek medical assistance if symptoms of pulmonary reaction develop (e.g. cough, dyspnoea, fever, chills) Avoid alkalinising agents as this reduces the antibacterial activity Avoid concomitant administration with magnesium trisilicate (reduces absorption) May colour urine brown/yellow – this is harmless 	<input type="checkbox"/>
Ensure adequate fluid intake (approx. 2.5L per day but avoid very large amounts due to risk of inadequate bladder contact with antibiotic) – should result in pale, straw coloured urine.	<input type="checkbox"/>

Advice	Provided (tick as appropriate)
Symptomatic (use of analgesia)	<input type="checkbox"/>
If patient has haematuria – seek medical assistance if haematuria persists or returns after successful treatment of UTI	<input type="checkbox"/>
Prevention of UTI - Hygiene / toilet habits <ul style="list-style-type: none"> • Do not 'hold on' – go to the toilet when you need to • Avoid double voiding • Voiding after sexual intercourse • Wipe from front to back • Wear loose fitting underwear/clothing • Wear cotton underwear • Avoid use of vaginal deodorants 	<input type="checkbox"/>
Patient information leaflet relating to medication is given to patient	<input type="checkbox"/>

Communication

Contact made with	Details (include time and method of communication)
Patient's regular General Practice (details)	Click or tap here to enter text.
Other	

Details of medication supplied and pharmacist supplying under the PGD

Medication supplied	Click or tap here to enter text.
Batch number and expiry	Click or tap here to enter text.
Print name of pharmacist	Click or tap here to enter text.
Signature of pharmacist	Click or tap here to enter text.
GPhC registration number	Click or tap here to enter text.

Patient Group Direction for the treatment of acute Urinary Tract Infection (UTI) in patients over 16 years

Notification of assessment and supply from community pharmacy

CONFIDENTIAL WHEN COMPLETED

Data protection confidentiality note: this message is intended only for the use of the individual or entity to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under law. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited.

GP name	Click or tap here to enter text.	Pharmacy Stamp
GP practice address	Click or tap here to enter text.	
	Click or tap here to enter text.	
The following patient has attended this pharmacy for assessment and potential treatment of UTI:		
Patient name	Click or tap here to enter text.	Pharmacist name Click or tap here to enter text.
Date of birth/CHI	Click or tap here to enter text.	
Patient address	Click or tap here to enter text.	GPhC number Click or tap here to enter text.
	Click or tap here to enter text.	
Postcode	Click or tap here to enter text.	Date Click or tap to enter a date.

Following assessment (Tick as appropriate)

Presenting symptoms			
Dysuria <input type="checkbox"/>	Urgency <input type="checkbox"/>	Haematuria <input type="checkbox"/>	
Frequency <input type="checkbox"/>	Polyuria <input type="checkbox"/>	Suprapubic tenderness <input type="checkbox"/>	
Urine dipstick results (optional)			
Nitrite '+ve' <input type="checkbox"/>	Leucocyte '+ve' <input type="checkbox"/>	Blood '+ve' <input type="checkbox"/>	Not taken <input type="checkbox"/>
Your patient has been given a 3 day course of:	Trimethoprim 200 mg tablets	<input type="checkbox"/>	
	Nitrofurantoin 100 mg MR capsules	<input type="checkbox"/>	
	Nitrofurantoin 50 mg capsules	<input type="checkbox"/>	
	Nitrofurantoin 50 mg tablets	<input type="checkbox"/>	
Your patient is unsuitable for treatment via PGD for the following reasons and has been referred: Click or tap here to enter text.		<input type="checkbox"/>	
Follow up by GP practice required for the following reasons: Click or tap here to enter text.		<input type="checkbox"/>	

Your patient has been advised to contact the practice if symptoms fail to resolve following treatment.

You may wish to include this information in your patient records.

Patient consent: I can confirm that the information is a true reflection of my individual circumstances and I give my consent to allow a pharmacist working under the terms of NHS Pharmacy First Scotland to provide the most appropriate advice and/or treatment for me. I also give my permission to allow the pharmacist to pass, to my own GP, details of this consultation and any advice given, or treatment provided. I have been advised that some of the information may be used to assess the uptake of the service, but this will be totally anonymous and not be attributable to any individual patient.	Consent received <input type="checkbox"/>
--	---

This form should now be sent to the patient's GP and a copy retained in the pharmacy.

Appendix 1.

For boards using nitrofurantoin, a renal function assessment is required.

*eGFR must be $>60\text{ml/min}$ for use of the nitrofurantoin PGD

**If eGFR is not available on Clinical Portal or ICE or other clinical system available because such a test appears never to have been performed, it can be assumed there has been no history or suspicion of renal problems and supply can be made if clinically appropriate.

